Stockholders' Equity

9 Months Ended

Sep. 28, 2018

Stockholders' Equity Note [Abstract]

Stockholders’ Equity

The following table reflects the activity of RSAs during the thirty-nine weeks ended September 28, 2018:



	Shares		Weighted Average Grant Date Fair Value
Unvested at December 29, 2017	329,761		$	16.69
Granted	311,671		23.61
Vested	(106,730	)	17.76
Forfeited	(1,506	)	17.13
Unvested at September 28, 2018	533,196		$	20.52

The Company granted 311,671 RSAs to its employees and directors at a weighted average grant date fair value of $23.61 each during the thirty-nine weeks ended September 28, 2018. These awards are a mix of time and performance based grants which will vest over periods of 3 months to 4 years. The Company recognized expense totaling $940 and $612 on its RSAs during the thirteen weeks ended September 28, 2018 and September 29, 2017, respectively, and $2,548 and $1,928 during the thirty-nine weeks ended September 28, 2018 and September 29, 2017, respectively.

At September 28, 2018, the total unrecognized compensation cost for unvested RSAs was $6,061 and the weighted-average remaining useful life was approximately 2.1 years. Of this total, $3,324 related to RSAs with time-based vesting provisions and $2,737 related to RSAs with performance-based vesting provisions. At September 28, 2018, the weighted-average remaining useful lives for time-based vesting and performance-based vesting RSAs were approximately 2.0 years and 2.2 years, respectively.

The Company recognized expense of $150 and $158 on stock options during the thirteen weeks ended September 28, 2018 and September 29, 2017, respectively, and $451 and $456 during the thirty-nine weeks ended September 28, 2018 and September 29, 2017, respectively. At September 28, 2018, the total unrecognized compensation cost for these options was $264 to be recognized over a weighted-average period of approximately 0.4 years.

As of September 28, 2018, there were 243,543 shares available for grant under the Company’s 2011 Omnibus Equity Incentive Plan. No share-based compensation expense has been capitalized.